Pharmacological modulation of tumor interstitial fluid pressure (IFP) to enhance intraperitoneal chemotherapy (IPC) by Gremonprez, Félix et al.
Pharmacological modulation of tumor interstitial fluid pressure (IFP) to enhance 
intraperitoneal chemotherapy (IPC). 
Gremonprez F.1; Izmer A.2; Vanhaecke F.²; Descamps B.³; Vanhove C.³; Pattyn P.1; Ceelen W.1 
1
: Laboratory of Experimental Surgery, Department of Gastrointestinal surgery, Ghent University Hospital, Ghent, Belgium 
²: Atomic and Mass Spectrometry, Department of Analytical Chemistry, Ghent University, Ghent, Belgium 
³: Department of Electronics and Information Systems, Ghent University, Ghent, BelgiumInfinity (iMinds-IBiTech-MEDISIP),  
Background 
The raised interstitial fluid pressure (IFP) in tumors hinders the penetration and uptake of cytotoxic 
drugs. Reduction of the IFP by anti-VEGF and/or anti-PDGFR therapy enhances delivery of systemic 
chemotherapy. It is unknown, whether these effects could also enhance intraperitoneal 
chemotherapy (IPC). 
Methods 
Bilateral subperitoneal injections of 1.5 x 106 HT-29 cells in 40 µl Matrigel were administered to 
Foxn1nu nude athymic mice (Harlan). On day 10 to 15, mice were administered either placebo, 
Imatinib (50 mg/kg daily), Pazopanib (100 mg/kg daily), or Bevacizumab (5 mg/kg 2x). At day 15, each 
mouse underwent an open IPC procedure with 150 mg/m² Oxaliplatin for 60’ at 37°C. Intraoperative 
measurements of tumor IFP (Samba Preclin®) and pO2 (Oxylite®) were performed. Tumor, blood, and 
perfusate samples were taken postoperatively. A second experiment made use of MRI (T2) on day 
14, 19 and 26 to assess tumor growth. In addition to the previously described groups, a sham group 
was included that did not receive oxaliplatin or pretreatment. DCE-MRI with Vistarem® (Guerbet) 
was also performed to determine tumor microvascularity and pretreatment effect.  
Results 
Tumor IFP was significantly lower in the Bevacizumab and Pazopanib groups (p<0,001). Interestingly, 
the hypoxic fraction (pO2 <5 mmHg) was also significantly increased in the Bevacizumab group 
(p=0,026). Tumor size and blood Pt concentration did not differ. Pt/P ratio (Oxaliplatin) was increased 
up to 2-3x in the tumor borders after Bevacizumab and Pazopanib treatment. Tumor growth was 
delayed mainly in the Bevacizumab and Pazopanib groups (p=0,0006). 
Conclusions 
Treatment with Bevacizumab and Pazopanib leads to a markedly reduced IFP in colorectal xenograft 
tumors. This effect allows for deeper penetration and higher concentration of Oxaliplatin in 
peritoneal tumors. The increased tumor growth delay confirms the potential of possible combination 
therapy. IHC and DCE-MRI (Mistar) analysis are currently ongoing.  
